Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies

Background: Immunizations against SARS-CoV-2 virus are now available and recommended, but the effect of additional dosing of the vaccine in immunocompromised MS patients is unknown. Methods: Part I - A retrospective chart review of MS patients who were vaccinated against SARS-CoV-2 and tested commer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallach, Asya I., Schiebel, Matthew, Picone, Mary Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072817/
https://www.ncbi.nlm.nih.gov/pubmed/35636275
http://dx.doi.org/10.1016/j.msard.2022.103856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072817/
https://www.ncbi.nlm.nih.gov/pubmed/35636275
http://dx.doi.org/10.1016/j.msard.2022.103856

Ejemplares similares